Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Puma Biotechnology's EV/EBITDA was 8.0× on Nov 11, 2026, against 4.5× a year earlier. Over the last 5 years it ranged from 2.6× to 27.6×, with a median of 6.1×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.0× | +2.5 |
| 2025 | Dec 31, 2025 | 5.5× | +2.4 |
| 2024 | Dec 31, 2024 | 3.1× | −3.5 |
| 2023 | Dec 29, 2023 | 6.6× | −1.3 |
| 2022 | Dec 30, 2022 | 7.9× | −11.6 |
| 2021 | Jul 30, 2021 | 19.5× | – |
See a number that looks wrong?